According to the Wisconsin State Journal, Madison’s Exact Sciences Corp. reported second-quarter results on Tuesday that beat analysts’ expectations.
Best known for its Cologuard test, the biomedical giant reported an $81 million second-quarter loss, or 45 cents per share, on $622.1 million in revenue. Analysts’ estimated a loss of 50 cents per share and revenue of $599 million.
Exact Sciences is projecting full-year revenue between $2.44 billion–$2.47 billion.
Last year’s second quarter results saw the molecular diagnostics company report a net loss of $166.1 million, or 94 cents per share, on $521.6 million in revenue.
Advertisement
